Cotrimoxazole, a drug combination of Trimethoprim, a folate antagonist, and Sulfamethoxazole, a sulfonamide, is commonly used in recipients of allogeneic hematopoietic SCT (HSCT) as prophylaxis against Pneumocystis jirovecii infection and for reactivation of Toxoplasmosis most commonly at a dose of 3 Â 160/800 mg per week with or without folinic acid supplementation. [1] [2] [3] [4] Cotrimoxazole is known for myelotoxicity, [5] [6] [7] [8] especially after long-term administration as prophylaxis in HIV patients, 9 and is therefore used cautiously after HSCT. The impact of this toxicity on neutrophil and platelet engraftment and duration of neutropenia/thrombocytopenia after allogeneic HSCT has not been determined. At our center, the policy to interrupt cotrimoxazole prophylaxis from the day of stem cell infusion (d þ 0) to hospital discharge (d þ 30), in order not to slow down engraftment of hematopoietic stem cells (HSCs), has been modified by the physician team from interrupted prophylaxis to continuous prophylaxis after a change in the transplant team directorship and then back again because of prevailing concerns over cotrimoxazole's toxicity in hematopoietic patients (17 patients in total).
This matched pair analysis based on data abstracted from the center database 10 compared, using the w 2 statistics for categorical variables and the Mann-Whitney U test for continuous variables, the 17 HSC recipients who received continued cotrimoxazole prophylaxis with 49 controls who received interrupted prophylaxis, matched for donor type (HLA-identical sibling; HLA-matched unrelated donor; HLA-mismatched unrelated donor), disease and age. Each patient was matched with at least two controls depending on the number of patients available in the database of consecutively transplanted patients (2-7, mean 3). The patients and controls were then compared for additional factors that may impact on engraftment, such as conditioning regimen intensity, stem cell source, stem cell dose, GVHD prophylaxis with T-cell depletion, donor-recipient sex combination and donor-recipient CMV serostatus; no differences were found (Table 1) .
Time to neutrophil and platelet engraftment was compared in patients and controls using the paired Friedman test. Survival was calculated using the Kaplan-Meier estimator, and the log rank test was used for comparison among groups. Neutrophil engraftment was defined as 40.5 g/L of granulocytes remaining stable over 3 days, and platelet engraftment as 420 g/L of granulocytes without transfusional support remaining stable over 5 days. Median time to neutrophil engraftment was 16 days (10-22) in patients receiving continued and 17 days (12-40) in patients receiving interrupted prophylaxis (P ¼ 0.9) (Figure 1) . Median time to platelet engraftment was 16 days (2-37) days with continued and 13 days (2-77) with interrupted Bone
prophylaxis (P ¼ 0.6). No statistically significant differences in speed of myeloid and platelet engraftment were noted between groups. No statistically significant differences for 3-year survival were noted between patients receiving continued (65 ± 23%) and those receiving interrupted prophylaxis (61 ± 15%), P ¼ 0.9. There were no cases of breakthrough infection.
Many SCT centers differ in their use of cotrimoxazole prophylaxis with regard to either interrupting or not, or in using non-myelotoxic drugs such as inhaled pentamidine. Here we show in a small case-control study that no differences were observed in the speed of myeloid and platelet engraftment on comparing patients receiving continued with those receiving interrupted prophylaxis. This study has several limitations. First, the number of patients is limited, thus lacking the power to detect small differences. Controls were chosen not by randomization, but by a case-control study design applied on the center database consisting of patients transplanted either before or after the period of continued prophylaxis. Controls were matched on some but not all pertinent variables. These findings require validation in larger studies. In summary, we show here that cotrimoxazole myelotoxicity does not appear to be a problem in these patients, at least not in the short term.
